<DOC>
	<DOC>NCT01399957</DOC>
	<brief_summary>Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.</brief_summary>
	<brief_title>Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients</brief_title>
	<detailed_description>Subjects will be evaluated before starting medication, throughout a 14week period after starting D-ER as well as at 12 and 18months following the start date of medication regardless of if they stayed on medication or not.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Confirmed clinical diagnosis of MS by McDonald criteria Prescribed ampyra (dalfampridine) as part of usual care, but have not yet started taking the medication before baseline visit Receive MS care at the Mandell MS center Cognitively able to understand directions and complete protocol (score of 22 or greater on the MMSE) 18 years of age or older Already began to take drug prior to baseline research visit Not planning to continue care at Mandell Center for at least 14 weeks after initiation of therapy Unwilling or unable to complete assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Dalfampridine-ER</keyword>
	<keyword>Walking speed</keyword>
</DOC>